Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 15;5:14. doi: 10.1038/s41523-019-0110-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — ZMC1 in combination with olaparib is a highly effective therapy for Brca1-deficient breast tumors. a Treatment efficacy of nude mice bearing implanted Brca1^−/−;p53^R172H/− tumors with DMSO (n = 7), ZMC1 (n = 6), Olaparib (n = 6) or ZMC1 + Olaparib (n = 7). b Individual tumor growth with corresponding treatment as in (a). c Disease specific survival of mammary tumor-bearing WAP-Cre;Brca1^f/f;Trp53^R172H/f mice treated with vehicle control (DMSO) (n = 9), ZMC1 (n = 10), olaparib (n = 7) or ZMC1 + olaparib (n = 6). d Overall survival of mammary tumor-bearing WAP-Cre;Brca1^f/f;Trp53^R172H/f mice treated with DMSO (n = 9), ZMC1 (n = 10), olaparib (n = 7) or ZMC1 + olaparib (n = 6). e The average log tumor volume of WAP-Cre;Brca1^f/f;Trp53^R172H/f tumor-bearing mice treated with ZMC1 (n = 10) olaparib (n = 7) or ZMC1 + olaparib (n = 6) versus post-injection time (in days). The fitted curves showed the log tumor volume of ZMC1, olaparib and ZMC1 + olaparib treatment groups and the corresponding point-wise 84% confidence intervals (shaded bands)